Women’s Heart Health Alert: SMART Clinical Trial Reveals Treatment Advantage for Aortic Stenosis

9 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
https://www.Heart-Valve-Surgery.com - A woman’s heart is not simply a small version of a man’s heart. There are stark differences in size, structure and function. Aortic stenosis is a prime example of the structural heart differences in men and women.

Until recently, there has been limited randomized controlled data regarding the treatment for aortic stenosis for patients with a small aortic annulus, most of whom are women. Medtronic’s SMART Clinical Trial results now shed light on this patient population.

To learn more, we recently traveled to the Women’s Heart Health Congressional Day in Washington, D.C., where we met with Dr. Roxana Mehan, who is a Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at Mount Sinai School of Medicine in New York City, New York.

Key questions addressed in this interview with Dr. Mehran include:

1. What are the fundamental challenges for women with heart disease?

2. Is it true that about 35 percent of women who are indicated for surgery because of aortic stenosis don’t get an aortic valve replacement?

3. Does heart valve disease (including aortic stenosis) impact women differently than men?

4. What is the SMART Clinical Trial and how does it relate to women's heart health and aortic stenosis?

5. What were the key one-year findings of the SMART Clinical Trial specific to the Medtronic Evolut TAVR?

6. What can female patients with narrow aortic valves do to improve women’s heart health?

To learn more about about the Medtronic Evolut TAVR treatment for aortic stenosis patients, please visit https://www.heart-valve-surgery.com/medtronic-tavr-procedure.
Category
Cardiology
Be the first to comment

Up Next